Not really. Like at all.The hope was that very low LDLs would eliminate traditional cardiovascular disease. That did not happen. As your starting LDL falls, the absolute benefit derived falls. Pharma has been extremely successful hiding that fact and getting KOLs to change guidelines so that most of the population is essentially recommended to be on statins + pcsk9inhibitors. This will have a marginal benefit in actual outcomes but will massively inflate US healthcare costs. The role for these a